Blood markers may forecast liver cancer treatment success
NCT ID NCT07734857
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study investigates whether substances in the blood can predict how patients with advanced liver cancer respond to a combination of atezolizumab and bevacizumab. Researchers will analyze leftover blood samples from routine tests in 100 patients to look for patterns linked to tumor shrinkage or growth. The goal is to develop a predictive model that could help personalize treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test that helps doctors identify which liver cancer patients are most likely to benefit from T+A therapy, avoiding unnecessary treatment for others.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. The findings may not be definitive enough to change clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?
- Breath of life: new test could sniff out gut cancers before they spread